▶Aprepitantis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Bosentanis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Hormone replacement therapydecreases the clearance of
dopamine receptor agonists(ropinirole). Monitor and adjust
dose.oStudy
▶Efavirenzis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Fosaprepitantis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶HIV-protease inhibitors(ritonavir)are predicted to decrease the
effects ofhormone replacement therapy.oAnecdotal
▶Hormone replacement therapyis predicted to increase the risk
of venous thromboembolism when given withlenalidomide.
rTheoretical
▶Modafinilis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Hormone replacement therapyis predicted to increase the
exposure tomonoamine-oxidase B inhibitors(selegiline). Avoid.
oStudy
▶Nevirapineis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶NSAIDs(etoricoxib)slightly increase the exposure tohormone
replacement therapy.oStudy
▶Hormone replacement therapyis predicted to increase the risk
of venous thromboembolism when given withpomalidomide.
rTheoretical
▶Rifabutinis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶Rifampicinis predicted to decrease the effects ofhormone
replacement therapy.oAnecdotal
▶St John’s Wortis predicted to decrease the efficacy ofhormone
replacement therapy.oTheoretical
▶Hormone replacement therapyis predicted to increase the risk
of venous thromboembolism when given withthalidomide.
rTheoretical
▶Oralhormone replacement therapyis predicted to decrease the
effects ofthyroid hormones.oTheoretical
Hydralazine→seeTABLE 8p. 848 (hypotension)
▶Diazoxideincreases the risk of severe hypotension when given
withhydralazine.rStudy→Also seeTABLE 8p. 848
Hydrochlorothiazide→see thiazide diuretics
Hydrocortisone→see corticosteroids
Hydroflumethiazide→see thiazide diuretics
Hydromorphone→see opioids
Hydroxycarbamide→seeTABLE 15p. 850 (myelosuppression)
▶Hydroxycarbamideincreases the risk of toxicity when given
withdidanosine. Avoid.rStudy
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
hydroxycarbamide. Public Health England advises avoid (refer
to Green Book).rTheoretical
▶Hydroxycarbamideincreases the risk of toxicity when given
withstavudine. Avoid.rStudy
Hydroxychloroquine
▶Hydroxychloroquineis predicted to decrease the effects of
agalsidase.oTheoretical
▶Antacidsdecrease the absorption ofhydroxychloroquine.
Separate administration by at least 4 hours.oStudy
▶Calcium salts(calcium carbonate)decrease the absorption of
hydroxychloroquine. Separate administration by at least
4 hours.oStudy
▶Hydroxychloroquineis predicted to decrease the efficacy of
oralcholera vaccine.oTheoretical
▶H 2 receptor antagonists(cimetidine)are predicted to decrease
the clearance ofhydroxychloroquine.oTheoretical
▶Lanthanumis predicted to decrease the absorption of
hydroxychloroquine. Separate administration by at least
2 hours.oTheoretical
▶Hydroxychloroquineis predicted to decrease the exposure to
laronidase. Avoid simultaneous administration.r
Theoretical
▶Hydroxychloroquineis predicted to increase the risk of
haematological toxicity when given withpenicillamine. Avoid.
rTheoretical
▶Hydroxychloroquineis predicted to decrease efficacyrabies
vaccine.oTheoretical
Hydroxyzine→see antihistamines, sedating
Hyoscine→seeTABLE 10p. 849 (antimuscarinics)
Ibandronic acid→see bisphosphonates
Ibrutinib→seeTABLE 15p. 850 (myelosuppression),TABLE 4p. 847
(antiplatelet effects)
FOOD AND LIFESTYLEAvoid food or drink containing bitter
(Seville) oranges as they are predicted to increase the
exposure to ibrutinib.
▶Antiarrhythmics(amiodarone)are predicted to increase the
exposure toibrutinib. Adjustibrutinibdose.rTheoretical
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure toibrutinib. Adjustibrutinibdose with moderate
inhibitors of CYP3A4.rStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toibrutinib. Avoid or adjustibrutinibdose.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure toibrutinib. Adjust
ibrutinibdose with moderate inhibitors of CYP3A4.r
Study
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to very markedly increase the exposure toibrutinib.
Avoid potent inhibitors of CYP3A4 or adjustibrutinibdose.
rStudy
▶Aprepitantis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toibrutinib. Adjustibrutinibdose with
moderate inhibitors of CYP3A4.rStudy
▶Cobicistatis predicted to very markedly increase the exposure
toibrutinib. Avoid potent inhibitors of CYP3A4 or adjust
ibrutinibdose.rStudy
▶Crizotinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Enzalutamideis predicted to decrease the exposure to
ibrutinib. Avoid or adjustibrutinibdose.rStudy
▶Fosaprepitantis predicted to slightly increase the exposure to
ibrutinib.oTheoretical
▶Grapefruit juiceis predicted to increase the exposure to
ibrutinib. Avoid.oTheoretical
▶HIV-protease inhibitorsare predicted to very markedly increase
the exposure toibrutinib. Avoid potent inhibitors of CYP3A4
or adjustibrutinibdose.rStudy
▶Idelalisibis predicted to very markedly increase the exposure
toibrutinib. Avoid potent inhibitors of CYP3A4 or adjust
ibrutinibdose.rStudy→Also seeTABLE 15p. 850
▶Imatinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Macrolides(clarithromycin)are predicted to very markedly
increase the exposure toibrutinib. Avoid potent inhibitors of
CYP3A4 or adjustibrutinibdose.rStudy
▶Macrolides(erythromycin)are predicted to increase the
exposure toibrutinib. Adjustibrutinibdose with moderate
inhibitors of CYP3A4.rStudy
▶Mitotaneis predicted to decrease the exposure toibrutinib.
Avoid or adjustibrutinibdose.rStudy→Also seeTABLE 15
p. 850
▶Netupitantis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy
▶Nilotinibis predicted to increase the exposure toibrutinib.
Adjustibrutinibdose with moderate inhibitors of CYP3A4.
rStudy→Also seeTABLE 15p. 850
▶Quinolones(ciprofloxacin)are predicted to increase the
exposure toibrutinib. Adjustibrutinibdose.rTheoretical
▶Rifampicinis predicted to decrease the exposure toibrutinib.
Avoid or adjustibrutinibdose.rStudyBNFC 2018 – 2019 Hormone replacement therapy—Ibrutinib 933
Interactions|Appendix 1A1